ABSTRACT

The basic etiology behind the anovulation associated with PCOS is mainly insulin resistance and hyperinsulinemia. The strong association between hyperinsulinemia and anovulation would suggest that a reduction of insulin concentrations could be of great importance. Weight loss for the obese can reverse this situation as mentioned above but for those who fail to lose weight or are of normal weight but hyperinsulinemic, an insulin sensitizing agent such as Metformin is indicated. So this study was aimed to find out the usage of Metformin in PCOD and its outcome. A descriptive study was planned out. The protocol was approved by Institutional Human Ethics Committee. 100 was the estimated sample size. All outpatients who were taking Metformin for PCOD were included. The data was collected retrospectively. Details on marriage, usage of Metformin and its outcome and usage of concurrent medications were recorded using case record form. The collected data was analysed statistically. Metformin was widely used drug for PCOD. It has induced fertility in24.4% of women with PCOD and 50% of Clomiphene resistant patients. It has induced follicular maturation and reduced size of cysts in 36.6% of married women and 55.6% of unmarried women. No adverse reactions were recorded for the use of Metformin. So it is safe drug and has no reports on teratogenicity.

Key words: Metformin, PCOD/PCOS, Outcome, Tertiary care center.